Catalyst Dossier · compiled by CeliA 🧫

Mirum Pharmaceuticals, Inc. (MIRM)

Pharmaceutical Preparations · market cap $6.5B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Mirum Pharmaceuticals (MIRM) is a commercial-stage rare-disease pharma focused on bile acid and liver disorders, with 2025 revenues of $521M and a market cap of ~$7.5B. Its pipeline spans multiple Phase 3 assets including Maralixibat (Biliary Atresia), Brelovitug (Chronic Hepatitis D), and Cholic Acid programs, with several high-importance binary readouts expected in H2 2026 through 2027. The company reported a net loss of $23M in 2025 on rapidly growing revenues, suggesting an approaching profitability inflection.

The catalyst path

2026-08-05Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Brelovitug 300 mgimp 9/10
2026-10-15 (est.)Phase 3 · Maralixibatimp 9/10
2027-04-15 (est.)Phase 2 · Volixibatimp 7/10
2027-06-15 (est.)Phase 3 · Brelovitug 900 mgimp 9/10
2027-06-30 (est.)Phase 3 · Bulevirtide 2 mg and Brelovitug - 300 mgimp 9/10

Pipeline

Asset	Phase	Indication
Volixibat	Phase 2	Primary Biliary Cholangitis
Maralixibat	Phase 3	Biliary Atresia
LUM001 (Maralixibat)	Phase 2	Alagille Syndrome
Cholic acid	Phase 3	Inborn Errors of Bile Acid Synthesis
Cholic Acids	Phase 3	Infantile Refsum's Disease
Ursodeoxycholic Acid	Phase 2	PBC
Low dose of MRM-3379	Phase 2	Fragile X Syndrome
LUM001	Phase 2	Alagille Syndrome
Blinded CDCA 250 mg TID	Phase 3	CTX
Brelovitug 900 mg	Phase 3	Chronic Hepatitis D Infection
Brelovitug 300 mg	Phase 3	Chronic Hepatitis D Infection
Bulevirtide 2 mg and Brelovitug - 300 mg	Phase 3	Chronic Hepatitis D Infection
Brelovitug (BJT-778)	Phase 3	Chronic Hepatitis D

Price & technical context

3-month

+32.7%

6-month

+59.3%

12-month

+155.8%

52-wk range

$50.27–$125.59

vs 50-day MA

+22.5%

vs 200-day MA

+42.6%

Realized vol

45.5%

Max drawdown

-27.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MIRM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.